系统性红斑狼疮与类风湿关节炎达标治疗:缓解与低疾病活动度的比较
本研究比较了100例SLE与100例匹配的血清阳性RA患者门诊记录,采用SDAI定义RA缓解/LDA,DORIS和LLDAS定义SLE缓解/LDA。SLE与RA的缓解或LDA比例无显著差异(88.5% vs 91.0%,P=0.2885),但SLE缓解比例更高(79.3% vs 69.4%,P=0.0018)。结论支持SLE采用达标治疗策略。
要点
- SLE与RA的缓解或LDA达标率相似(88.5% vs 91.0%,P=0.2885)。
- SLE缓解比例高于RA(79.3% vs 69.4%,P=0.0018)。
- SLE的缓解/LDA定义成功借鉴了RA的定义。
核心结论
- 当前治疗下SLE与RA患者达标治疗目标达成率相似。
- SLE的缓解和LDA定义成功借鉴了RA的定义。
- 有利状态的达标率支持在SLE中采用达标治疗策略。
研究设计与样本
- 比较100例SLE与100例匹配的血清阳性RA患者的门诊记录数据。
- 纳入2021年8月至2023年1月间至少连续三次门诊随访的患者。
- 每次随访记录SLEDAI-2K(SLE)、SDAI(RA)和视觉模拟量表(VAS)。
主要发现
- SLE患者392次随访中347次(88.5%)达到缓解或LDA,RA患者389次随访中354次(91.0%)达到(P=0.2885)。
- SLE缓解比例79.3%高于RA的69.4%(P=0.0018)。
- 低疾病活动度时SLE与RA的医生整体评估(PhGA)无显著差异,缓解时SLE仅略高(P=0.0002)。
- 活动性RA较活动性SLE的C反应蛋白升高(P=0.0107),但红细胞沉降率相似。
关键数值与推荐
- RA缓解和LDA由SDAI截断值定义。
- SLE缓解由DORIS定义,LDA由LLDAS定义。
临床怎么用
- SLE可参照RA的达标治疗模式,以DORIS缓解和LLDAS为目标管理疾病。
- 临床评估SLE疾病活动度时可结合SLEDAI-2K和医生整体评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To compare the proportion of patients in remission and low disease activity (LDA) between rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). METHODS: Outpatient record data of 100 patients with SLE and of 100 matched patients with seropositive RA, with at least three consecutive outpatient visits each between August 2021 and January 2023 were compared. Documentation at every visit included SLE Disease Activity Index 2000 (SLEDAI-2K) for SLE, Simplified Disease Activity Index (SDAI) for RA and visual analogue scales (VAS). Remission and LDA were defined by SDAI cut-offs in RA and Definition of Remission in SLE (DORIS) remission and Lupus Low Disease Activity State (LLDAS) in SLE. RESULTS: Remission or LDA were present in 347 (88.5%) of 392 visits of SLE and 354 (91.0%) of 389 visits of RA patients (P = 0.2885). Remission was more common in SLE (79.3%) than RA (69.4%) data points (P = 0.0018). Physician global assessment (PhGA) was not significantly different between SLE and RA patients in low disease activity, and only slightly higher in SLE in remission (P = 0.0002). C-reactive protein (CRP) was increased (P = 0.0107) but the erythrocyte sedimentation rate was similar in active RA vs active SLE. CONCLUSION: Treat-to-target (T2T) goals were similarly met for SLE and RA patients on current treatment. Despite differences between the diseases and according to differences in definitions, these data suggest that the SLE definitions for remission and LDA were successfully modelled on those of RA. The rates with which favourable states were noted support the T2T approach in SLE.
引用
- Hüther K, Leuchten N, Aringer M, et al. Treating-to-target: remission and low disease activity in systemic lupus erythematosus versus rheumatoid arthritis. Rheumatology (Oxford). 2026. PMID: 41578961. doi:10.1093/rheumatology/keag045
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。